Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan versus irinotecan plus panitumumab and versus irinotecan plus ciclosporin

Trial Profile

A randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan versus irinotecan plus panitumumab and versus irinotecan plus ciclosporin

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PICCOLO
  • Most Recent Events

    • 12 Jul 2021 Results assessing effect of anti-EGFR therapy on survival in different consensus molecular subtypes (CMSs) and stratified by primary tumour location retrospectively in two studies (COIN & PICCOLO), published in the British Journal of Cancer.
    • 22 Apr 2021 Results (n=274) evaluating Artificial intelligence-assisted amphiregulin and epiregulin immunohistochemistry predicts panitumumab benefit in RAS wild-type metastatic colorectal cancer published in the Clinical Cancer Research
    • 17 Jan 2021 Results of retrospective biomarker study within the PICCOLO trial, evaluating AI assisted immunohistochemical tumor amphiregulin and epiregulin expression, presented at the 2021 Gastrointestinal Cancers Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top